Skip to main content

Table 2 Potency of EG22 and ZSM02 on MGMT-proficient and deficient human tumour cells (IC50 μM)

From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

  A427 A427 MGMT A549 T98 DU145
MGMT status + + + +
EG22 3.8 ± 0.12 2.9 ±0.21 1.6 ±0.16 1.7 ± 0.16 6.0 ±0.55
ZSM02 2.9 ± 0.49 3.7 ± 0.23 2.0 ± 0.50 4.3 ± 1.6 4.7 ± 0.11
ANI >100 >100 >100 >100 >100
TMZ 34 ± 4.0 305 ± 11 337 ± 28 516 ± 72 598 ± 59
ANI + TMZ 5.0 ± 0.82 41 ± 1.1 47 ± 11 80 ± 10 78 ± 4.6